Genome-wide association studies in pharmacogenomics: Successes and lessons

Alison A. Motsinger-Reif, Eric Jorgenson, Mary V. Relling, Deanna L. Kroetz, Richard M Weinshilboum, Nancy J. Cox, Dan M. Roden

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

OBJECTIVE: As genotyping technology has progressed, genome-wide association studies (GWAS) have matured into efficient and effective tools for mapping genes underlying human phenotypes. METHODS: Recent studies have shown the utility of the GWAS approach for examining pharmacogenomic traits, including drug metabolism, efficacy, and toxicity. RESULTS: Application of GWAS to pharmacogenomic outcomes presents unique challenges and opportunities. CONCLUSION: In the current review, we discuss the potential promises and potential caveats of this approach specifically as it relates to pharmacogenomic studies. Concerns with study design, power and sample size, and analysis are reviewed. We further examine the features of successful pharmacogenomic GWAS, and describe consortia efforts that are likely to expand the reach of pharmacogenomic GWAS in the future.

Original languageEnglish (US)
Pages (from-to)383-394
Number of pages12
JournalPharmacogenetics and Genomics
Volume23
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Genome-Wide Association Study
Pharmacogenetics
Chromosome Mapping
Sample Size
Technology
Phenotype
Pharmaceutical Preparations

Keywords

  • drug metabolism
  • drug response
  • genome-wide association
  • genome-wide association studies
  • pharmacogenetic
  • pharmacogenomic
  • toxicity

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)

Cite this

Motsinger-Reif, A. A., Jorgenson, E., Relling, M. V., Kroetz, D. L., Weinshilboum, R. M., Cox, N. J., & Roden, D. M. (2013). Genome-wide association studies in pharmacogenomics: Successes and lessons. Pharmacogenetics and Genomics, 23(8), 383-394. https://doi.org/10.1097/FPC.0b013e32833d7b45

Genome-wide association studies in pharmacogenomics : Successes and lessons. / Motsinger-Reif, Alison A.; Jorgenson, Eric; Relling, Mary V.; Kroetz, Deanna L.; Weinshilboum, Richard M; Cox, Nancy J.; Roden, Dan M.

In: Pharmacogenetics and Genomics, Vol. 23, No. 8, 08.2013, p. 383-394.

Research output: Contribution to journalArticle

Motsinger-Reif, AA, Jorgenson, E, Relling, MV, Kroetz, DL, Weinshilboum, RM, Cox, NJ & Roden, DM 2013, 'Genome-wide association studies in pharmacogenomics: Successes and lessons', Pharmacogenetics and Genomics, vol. 23, no. 8, pp. 383-394. https://doi.org/10.1097/FPC.0b013e32833d7b45
Motsinger-Reif, Alison A. ; Jorgenson, Eric ; Relling, Mary V. ; Kroetz, Deanna L. ; Weinshilboum, Richard M ; Cox, Nancy J. ; Roden, Dan M. / Genome-wide association studies in pharmacogenomics : Successes and lessons. In: Pharmacogenetics and Genomics. 2013 ; Vol. 23, No. 8. pp. 383-394.
@article{af57666cb2244a80bea09316b5318489,
title = "Genome-wide association studies in pharmacogenomics: Successes and lessons",
abstract = "OBJECTIVE: As genotyping technology has progressed, genome-wide association studies (GWAS) have matured into efficient and effective tools for mapping genes underlying human phenotypes. METHODS: Recent studies have shown the utility of the GWAS approach for examining pharmacogenomic traits, including drug metabolism, efficacy, and toxicity. RESULTS: Application of GWAS to pharmacogenomic outcomes presents unique challenges and opportunities. CONCLUSION: In the current review, we discuss the potential promises and potential caveats of this approach specifically as it relates to pharmacogenomic studies. Concerns with study design, power and sample size, and analysis are reviewed. We further examine the features of successful pharmacogenomic GWAS, and describe consortia efforts that are likely to expand the reach of pharmacogenomic GWAS in the future.",
keywords = "drug metabolism, drug response, genome-wide association, genome-wide association studies, pharmacogenetic, pharmacogenomic, toxicity",
author = "Motsinger-Reif, {Alison A.} and Eric Jorgenson and Relling, {Mary V.} and Kroetz, {Deanna L.} and Weinshilboum, {Richard M} and Cox, {Nancy J.} and Roden, {Dan M.}",
year = "2013",
month = "8",
doi = "10.1097/FPC.0b013e32833d7b45",
language = "English (US)",
volume = "23",
pages = "383--394",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Genome-wide association studies in pharmacogenomics

T2 - Successes and lessons

AU - Motsinger-Reif, Alison A.

AU - Jorgenson, Eric

AU - Relling, Mary V.

AU - Kroetz, Deanna L.

AU - Weinshilboum, Richard M

AU - Cox, Nancy J.

AU - Roden, Dan M.

PY - 2013/8

Y1 - 2013/8

N2 - OBJECTIVE: As genotyping technology has progressed, genome-wide association studies (GWAS) have matured into efficient and effective tools for mapping genes underlying human phenotypes. METHODS: Recent studies have shown the utility of the GWAS approach for examining pharmacogenomic traits, including drug metabolism, efficacy, and toxicity. RESULTS: Application of GWAS to pharmacogenomic outcomes presents unique challenges and opportunities. CONCLUSION: In the current review, we discuss the potential promises and potential caveats of this approach specifically as it relates to pharmacogenomic studies. Concerns with study design, power and sample size, and analysis are reviewed. We further examine the features of successful pharmacogenomic GWAS, and describe consortia efforts that are likely to expand the reach of pharmacogenomic GWAS in the future.

AB - OBJECTIVE: As genotyping technology has progressed, genome-wide association studies (GWAS) have matured into efficient and effective tools for mapping genes underlying human phenotypes. METHODS: Recent studies have shown the utility of the GWAS approach for examining pharmacogenomic traits, including drug metabolism, efficacy, and toxicity. RESULTS: Application of GWAS to pharmacogenomic outcomes presents unique challenges and opportunities. CONCLUSION: In the current review, we discuss the potential promises and potential caveats of this approach specifically as it relates to pharmacogenomic studies. Concerns with study design, power and sample size, and analysis are reviewed. We further examine the features of successful pharmacogenomic GWAS, and describe consortia efforts that are likely to expand the reach of pharmacogenomic GWAS in the future.

KW - drug metabolism

KW - drug response

KW - genome-wide association

KW - genome-wide association studies

KW - pharmacogenetic

KW - pharmacogenomic

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=84872895907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872895907&partnerID=8YFLogxK

U2 - 10.1097/FPC.0b013e32833d7b45

DO - 10.1097/FPC.0b013e32833d7b45

M3 - Article

C2 - 20639796

AN - SCOPUS:84872895907

VL - 23

SP - 383

EP - 394

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 8

ER -